SUPPLEMENT PROTOCOL - AN OVERVIEW

less than both equally Drake’s and Lynch’s products, the price of deleterious mutations is what drives mutation premiums down (Drake 1991; Lynch 2010; Sung et al. 2012). consequently, less than both equally products, a rise in the average expense of mutations would lead to a minimize in mutation costs. To examine this, Drake examined mutation p